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Overexpression of the chondroitin sulfate proteoglycan 4 (CSPG4) has been associated 
with the pathology of multiple types of such as melanoma, breast cancer, squamous 
cell carcinoma, mesothelioma, neuroblastoma, adult and pediatric sarcomas, and some 
hematological cancers. CSPG4 has been reported to exhibit a role in the growth and sur-
vival as well as in the spreading and metastasis of tumor cells. CSPG4 is overexpressed 
in several malignant diseases, while it is thought to have restricted and low expression in 
normal tissues. Thus, CSPG4 has become the target of numerous anticancer treatment 
approaches, including monoclonal antibody-based therapies. This study reviews key 
potential anti-CSPG4 antibody and immune-based therapies and examines their direct 
antiproliferative/metastatic and immune activating mechanisms of action.
Keywords: CSPG4, MCSP,  HMw-MAA, NG2, melanoma, triple-negative breast cancer, immunotherapy, antibodies
iNTRODUCTiON
Recent advances in the field of cancer immunotherapy, involving specific targeting modalities like 
monoclonal antibodies or chimeric antigen receptor (CAR) T cell therapies, depend on the identi-
fication of appropriate surface antigens. The search for appropriate targets is especially important 
for certain malignancies such as triple-negative breast cancer (TNBC), which lack expression of the 
human epidermal growth factor receptor 2 (HER2/neu), estrogen or progesterone receptors, thus 
rendering them insensitive to available targeted therapies.
Chondroitin sulfate proteoglycan 4 (CSPG4) is a highly glycosylated transmembrane protein, and 
a member of the chondroitin sulfate group of glycosaminoglycans (GAGs). CSPG4, also referred 
to as melanoma-associated chondroitin sulfate proteoglycan (MCSP), high-molecular-weight 
melanoma-associated antigen (HMW-MAA), or neuron-glial antigen 2 (NG2), was first associated 
with malignant melanoma and subsequently implicated in the pathology of other solid tumors of 
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different origins, as well as of hematological cancers (1). It has 
been investigated as a potential immunotherapy target due to its 
restricted/low distribution in normal tissues and overexpression 
in certain tumors at different disease stages, and based on evidence 
for multiple roles in supporting tumor growth and dissemination. 
Together, long-emerging studies point to CSPG4 as a promising 
target for cancer therapies, including immunotherapies with 
monoclonal antibodies. In this review, we summarize reported 
functions of CSPG4 in cancer and we examine the development 
of ongoing immunotherapy strategies, most notably monoclonal 
antibodies that target CSPG4.
CSPG4 NORMAL TiSSUe DiSTRiBUTiON, 
STRUCTURe, AND PHYSiOLOGiCAL 
FUNCTiONS
Chondroitin sulfate proteoglycan 4 is heterogeneously expressed 
on normal tissues such as mesenchymal stromal cells—adult 
progenitor cells, which have been suggested to lose its expression 
during terminal differentiation (2). Early immunofluorescence/
immunohistochemisry data on the distribution of CSPG4 in 
normal tissues suggest it is expressed in nevi, epidermis and hair 
follicles but not detected in brain, thyroid, thymus, lung, liver, 
ureter, testis, spleen, ovary, or peripheral nerves (3). In another 
early study, immunohistochemical analysis of fetal and adult 
human tissues suggest CSPG4 distribution in the adrenal cortex, 
liver, choroid and small intestine in the fetus and in adult periph-
eral nerves, liver, salivary glands, bladder, lung bronchial glands 
and sebaceous glands (4). In more recent studies, expression of 
CSPG4 and its rat ortholog has been reported at low or moderate 
levels on neuronal glial cells, arteriolar pericytes, smooth muscle 
cells, macrophages, melanocytes, articular chondrocytes, and 
others (5–11). At the RNA level, CSPG4 expression has been 
recently reported in skin, trachea, veins, lung, heart, muscle, 
diaphragm, adipose tissue, uterus, prostate, thymus, spleen, bone 
marrow, and gastrointestinal tissue, but importantly at 6.6 times 
lower levels than in tumors (12).
Its physiological functions are not completely understood and 
multiple studies report specific roles in different tissues through-
out development. In placenta formation, the expression of 
CSPG4 on extravillous trophoblasts has been implicated in their 
differentiation and migration (13). CSPG4 is also proclaimed to 
be involved in angiogenesis and vascularization. Using murine 
in vivo models, NG2 was shown to induce de novo vascularization 
of otherwise the avascular corneal tissue, suggesting an important 
role in angiogenesis (14). Further reports suggest the involvement 
of CSPG4 in glial and oligodendrocyte formation and neuronal 
network regulation, epithelial keratinocyte replenishment, and 
epidermal stem cell positioning and homeostasis (15, 16).
Although a full understanding of the physiological roles 
of CSPG4 is still required, all reports suggest it is ubiquitously 
involved in multiple tissue development and homeostasis pro-
cesses, and its roles may be differentially modulated based on the 
nature of the local tissue microenvironment (17). The regulation 
of CSPG4 expression is reported to be strongly affected by inflam-
matory cytokines such as TNF-α, interleukin (IL)-1α, IFN-γ, and 
TGF-β and hypoxia-induced mechanisms involving hypoxia-
inducible factors. Furthermore, CSPG4 expression was described 
to depend on epigenetic pathways, certain transcription factors 
and microRNAs (see Ampofo et al. for review).
Its functional versatility could be explained by its protein 
scaffold structural characteristics (Figure  1). CSPG4 is a type 
I single pass transmembrane protein which exists as a core 
glycoprotein and chondroitin sulfate-decorated proteoglycan 
(18). Studies with the rat ortholog state CSPG4 consists of a 
large extracellular portion, a transmembrane domain and a short 
intracellular portion (19). The extracellular portion comprises 
three distinct domains. Located furthest from the membrane, D1 
is composed of two laminin G-type subdomains and is abundant 
in disulfide bonds, important for the stability of tertiary structure. 
This domain is potentially involved in the interactions with the 
extracellular matrix (20). The middle domain, D2, comprises 15 
CSPG4 specific repeats containing several potential glycosylation 
and chondroitin sulfate binding sites. The CS decoration may 
confer different attributes, including interaction with integrins 
and metalloprotease activation (21, 22). It is presently unclear 
whether CSPG4 is characterized with different glycosylation/
glycanation patterns in normal or cancerous tissues. The D2 
domain has also been proposed to directly bind collagens (23, 24). 
Although CSPG4 has no reported enzymatic functions, murine 
ortholog studies suggest it may bind growth factors and present 
them to receptor tyrosine kinases (RTKs), thus acting as a RTK 
coreceptor (25, 26).
Domain D3 is the one proximal to the cellular membrane, and 
contains putative protease cleavage sites as well as carbohydrate 
decoration, suggesting potential interactions with lectins and 
integrins (27, 28). Proteolytic cleavage may also allow ectodomain 
shedding. In support, levels of soluble CSPG4 have been reported 
in the sera of healthy individuals and patients with melanoma 
(29). The presence of soluble CSPG4 within circulation has been 
proposed as a potential diagnostic biomarker to aid melanoma 
detection and classification at the vertical growth phase (29). 
Moreover, CSPG4 may undergo endocytic recycling mediated by 
the endocytic receptor Stonin1 (30). Thus, endocytosis and ecto-
domain shedding of CSPG4 may point to different mechanisms 
involved in the turnover of membrane-bound protein.
The intracellular portion of CSPG4 is characterized by the 
presence of a threonine- and a proline-rich motif and a PDZ 
[postsynaptic density protein 95 (PSD-95)—Drosophila disc large 
tumor suppressor (Dlg1)—Zona occludens 1 (ZO-1)] domain 
(31, 32). The threonine motifs serve as kinase phosphoacceptor 
sites for protein kinase C α (PKCα) and extracellular signal-
regulated kinase 1/2 (ERK1/2) (33, 34). The proline-rich domain 
and the PDZ domain most likely function as protein scaffolds 
for other intracellular proteins (31). The structural characteristics 
of CSPG4 may confer possible functions as a signaling media-
tor molecule, connecting the extracellular matrix (ECM) with 
two main intracellular signaling cascades—the integrin-focal 
adhesion kinase (FAK) axis through integrin interactions and 
the mitogen-activated protein kinase (MAPK) pathway through 
activation of RTKs and ERK1/2 (33, 35, 36). These may bestow 
functional attributes that could encompass promotion of cellular 
survival, proliferation, and motility. Importantly, studies with 
FiGURe 1 | Structure and functions of chondroitin sulfate proteoglycan 4 (CSPG4) and antibody-based treatment approaches. (A) Schematic representation of 
CSPG4 proposed structure and functions in cancer. CSPG4 has three extracellular domains: D1, D2 and D3. Domain 1 (D1) consists of two laminin G like domains 
(L1 and L2) proposed to interact with the extracellular matrix (ECM). Domain 2 (D2) consists of 15 CSPG repeats containing chondroitin sulfate chain decoration. It is 
proposed to interact with integrins and ECM proteins, and to bind and present growth factors to receptor tyrosine kinases. Domain 3 (D3) contains putative protease 
cleaving sites and may be involved in protein shedding. The cytoplasmic tail containing proline- and threonine-rich sites, is thought to interact with different proteins 
and function as a phosphoacceptor site for the extracellular signal-regulated kinase 1/2 (ERK1/2), respectively. The PDZ domain is involved in protein scaffolding 
functions. CSPG4 is therefore implicated in cellular signaling pathways, including the mitogen-activated protein kinase pathway, through the receptor tyrosine 
kinase-ERK1/2 axis and the focal adhesion kinase (FAK) pathway, through the ECM–fibronectin–integrin axis. These may promote survival, proliferation and 
migration, cytoskeletal reorganization that may promote motility, invasiveness, and angiogenesis. (B) Key cancer antibody immunotherapy strategies targeting 
CSPG4: 1. Classic antibody approaches, functioning through two mechanisms—direct blockade of cell signaling functions and antibody dependent cellular 
cytotoxicity/phagocytosis (ADCC/ADCP) mediated by immune effector cells like macrophages and NK cells; 2. Combination of CSPG4 blocking antibodies and 
BRAF inhibitors; 3. Cytolytic fusion proteins (CFPs); 4. Bispecific T cell engager antibodies (BiTEs) redirecting cytotoxic T cells toward CSPG4 overexpressing cells; 
5. Chimeric antigen receptor (CAR) T cells, redirecting genetically modified T cells toward CSPG4 overexpressing cells.
3
Ilieva et al. CSPG4—A Cancer Antibody Immunotherapy Target
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1911
4Ilieva et al. CSPG4—A Cancer Antibody Immunotherapy Target
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1911
NG2 knockout mice suggest that deletion of this antigen is not 
lethal (37).
Therefore, research studies into CSPG4 point to stem cell 
origin, multiple functions in tissue development, together with 
regulation of expression by inflammation, hypoxia, decreased 
methylation mechanisms, as well as specific protein scaffolding 
structure and reported roles in cell signaling. These features may 
also translate to contributions in cancer pathology in several 
tumor types.
CSPG4 eXPReSSiON AND PUTATive 
PATHOLOGiCAL FUNCTiONS iN CANCeR
Early reports associated overexpression of CSPG4 with malignant 
melanomas, and more recently its enhanced expression has been 
identified in other cancer types. Despite these developments, the 
exact involvement of CSPG4 in the etiology of cancer is widely 
unknown.
It remains unclear whether CSPG4 has a role in tumor 
initiation or its expression only accumulates in tumors as a 
secondary tumor-associated event. Overexpression of CSPG4 
has not been reported to be a result of genetic aberrations such 
as gene amplifications or chromosome translocation, suggest-
ing CSPG4 may not be a primary driver in the onset of cancer. 
Even though its expression is not connected to the onset of 
epithelial tumors or hematological cancers, it has been linked 
to the putative mesenchymal stem cell origin of sarcomas and 
the epithelial–mesenchymal transition in melanoma, thought to 
be important for malignant transformation (36, 38–40). Several 
reports point toward potential roles in cancer growth and 
dissemination. Expression of the CSPG4 rodent homolog has 
been shown to localize in the invasive front of the filopodia of 
oligodendrocytes, suggesting involvement in mediating tumor 
cell motility and cancer dissemination (38, 41). In support, 
immunohistochemistry data evaluating CSPG4 expression in 
human melanoma claim higher levels in metastatic lesions than 
in primary tumors, and CSPG4 mRNA expression was reported 
to be predictive of metastasis formation in soft tissue sarcoma 
patients (6, 42).
Furthermore, CSPG4 is believed to contribute to cancer 
growth and progression through promotion of angiogenesis. 
Using cell line and patient derived glioblastoma xenografts in 
nude mice, Wang et  al. reported that NG2 RNA interference 
in vivo decreased tumor volume and vasculature (43). In addition, 
a retrospective study focused on germline polymorphisms related 
to the function of pericytes in colorectal cancer, identified a 
CSPG4 polymorphism to be predictive of lower progression-free 
survival in patients treated with the monoclonal antibody (mAb) 
bevacizumab—specific for the vascular endothelial growth factor 
(44). More evidence is required to clarify the exact mechanism 
through which CSPG4 promotes angiogenesis in cancer.
Disparate reports therefore point to potential contributions 
of CSPG4 in cancer growth, vascularization, dissemination, 
and metastasis (Figure 1). These may provide opportunities for 
therapeutic interventions targeting CSPG4 and multiple cancer-
associated pathways this molecule may be involved in.
expression in Neuroectodermal Cancers
Malignant Melanoma
Among the neuroectodermal tumors, malignant melanoma is the 
most thoroughly characterized in terms of CSPG4 expression and 
functions (36). CSPG4 is the only well characterized cell surface 
melanoma-associated antigen and it has been examined as a 
potential target employing different therapeutic approaches. It is 
expressed in over 70% of melanomas, and its expression has been 
detected throughout different disease stages.
Multiple studies demonstrate the importance of a functional 
full length CSPG4 for the survival, growth, and motility of mela-
noma tumor cells in vitro and tumor formation in vivo. CSPG4 
contributes to enhanced activation of the integrin-FAK pathway 
through interaction with ECM components, which leads to integ-
rin clustering and subsequent downstream signaling, cytoskeletal 
reorganization and increased motility and invasiveness (14, 21, 
27, 33, 35). On the other hand, CSPG4 facilitates the MAPK 
pathway through activation of ERK1 and ERK2. ERK1 and 2 
can then regulate the microphthalmia-associated transcription 
factor, which then alters the levels of vital proteins—increasing 
the expression of fibronectin, but also repressing the expression 
of E-cadherin, both of which have been shown to be associated 
with metastasis (45–49).
Since a big proportion of melanomas feature constitutively 
active MAPK pathway due to mutations in the gene encoding 
the serine/threonine-protein kinase, BRAF, several groups have 
investigated the effect of CSPG4 in BRAF mutant melanoma 
in  vitro. Full length CSPG4 is required for maximal activation 
of ERK1/2, and siRNA inhibition of CSPG4 leads to a reduction 
in ERK signaling (50). Importantly, in vitro studies report that 
specific small molecule inhibitors for mutant BRAF can syner-
gize with the 225.28 anti-CSPG4 mAb in inhibiting cell growth 
and proliferation (51). On the other hand, ERK1/2 signaling 
blockade leads to reduced CSPG4-dependent cancer cell motility 
(50). These reports suggest that alongside constitutive activation 
of BRAF, CSPG4 may additionally promote MAPK pathway 
activation.
Glioma
Expression of CSPG4 is found in subsets of normal glial cells in 
developing and adult central nervous system (see Dimou and 
Gallo for a review) (52). Although less well examined than mela-
noma, CSPG4 expression has also been associated with gliomas 
that originate from astrocytes, such as glioblastoma multiforme 
(GBM) (53–55). In a study analyzing mRNA expression data 
sourced from The Cancer Genome Atlas, CSPG4 mRNA levels 
were reported to be elevated compared to normal tissue controls 
(54). As in melanoma, functions of CSPG4 in glioblastoma are 
believed to be related to malignant progression through facilitat-
ing tumor cell interactions with collagen and promoting angio-
genesis (56, 57). Interestingly, as reviewed by Ampofo et al., the 
expression levels of both CSPG4 and the platelet-derived growth 
factor receptor alpha (PDGFR-α) in glioma are downregulated 
by micro RNA miR192-2 (17). Moreover, CSPG4 and PDGFR-α 
have been reported to interact and enhance cell proliferation 
upon PDGF stimulation. Therefore, miR129-2 has been proposed 
by Ampofo et al., to have therapeutic potential in glioma. CSPG4 
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has also been associated with pediatric brain tumors such as 
medulloblastoma (58–60).
expression in epithelial Cancers
Breast Cancer
Another cancer type of epithelial origin, whose associations 
with CSPG4 have attracted a surge of interest, is breast cancer. 
Expression of CSPG4 in triple-negative breast cancer (TNBC) in 
particular is of special value, since this subtype represents an area 
of unmet need for novel targeted therapies. TNBCs, comprising 
15% of all breast cancers, lack expression of the estrogen, proges-
terone and the HER2. Their triple-negative status makes them 
insensitive to the current hormone and HER2 targeted therapies. 
TNBCs are more aggressive with worse prognosis compared with 
other breast cancer types with no targeted therapies available, 
and therefore, novel targets and treatment options are urgently 
required.
Chondroitin sulfate proteoglycan 4 expression was described 
in TNBC primary lesions and metastatic tumor cells from pleural 
infusions, including cancer stem cells (61). Although CSPG4 
expression does not appear to be expressed exclusively by basal 
breast cancers including TNBCs, its expression may be associated 
with poor prognosis and relapse in breast cancers (62). Findings 
to-date indicate a link between the expressions of carbohydrate 
sulfotransferase-11 (encoded by CHST11) which is involved in 
decorating CSPG4 with chondroitin sulfate and the metastatic 
behavior of triple-negative breast cancer cells (63). Reportedly, 
CHST11 is overexpressed in aggressive breast cancers and 
facilitates the interaction between p-selectin and CSPG4. These 
observations are in line with the proposed role of CSPG4 as a 
mediator between the ECM and intracellular signaling pathways 
and a metastatic driver, P-selectin. The latter is thought to allow 
cancer cells to resist the immune response, and to support bind-
ing to endothelial cells, and thus hematogenous spread (64). 
Further research is required to elucidate the CSPG4 pathological 
contributions to breast cancer formation and progression.
Head and Neck Cancers
Head and neck squamous-cell carcinomas (HNSCC) normally 
have a poor prognosis, with a 5-year survival rate of around 
40–50%. Warta et al. recently reported CSPG4 to be significantly 
overexpressed in HNSCC cells (65). Furthermore, high expression 
in patient lesions was found to correlate with poorer prognosis 
compared with low expression of CSPG4 (65). The study noted 
that few biomarkers are currently available to predict survival in 
HNSCC, and that CSPG4 could in future serve as a prognostic 
indicator.
expression in Mesenchymal Cancers
A recent study using murine sarcoma models demonstrated that 
both malignant bone and soft tissue sarcomas, as well as benign 
desmoid tumors could originate from CSPG4-expressing peri-
cyte cells (66). Nevertheless, the authors did not investigate the 
specific implications of CSPG4 expression in the tumor formation 
process. Another potential mechanism described by Cattaruzza 
et al. suggests an interplay between CSPG4 and type VI collagen 
in the progression of soft-tissue sarcoma (67). The same study 
reports upregulation of both CSPG4 and collagen type VI in 
soft-tissue sarcoma lesions and suggests that the combination can 
predict metastasis and poor clinical prognosis. However, the role 
of CSPG4 in mesenchymal tumors is yet to be revealed.
expression in Hematological Cancers
Chondroitin sulfate proteoglycan 4 expression has also been 
reported in acute myeloid leukemia and acute lymphoblastic 
leukemia (ALL), while it is not expressed on normal lympho-
cytes, granulocytes or hematopoietic progenitor cells (68–71). 
Remarkably, for both ALL and AML, CSPG4 expression strongly 
correlated with the 11q23 gene rearrangement of the KMT2A 
gene encoding the lysine methyltransferase 2A. The mechanisms 
behind this correlation are still unknown. Nicolosi et al., shared 
an unpublished observation that a potential function of CSPG4 
in leukemic malignancies could be induction of drug resistance, 
based on CSPG4 in vitro knock-in experiments in mixed lineage 
leukemia gene bearing cells, resulting in increased drug trans-
porter expression (38).
CSPG4 AND CROSS-TALK wiTH THe 
iMMUNe SYSTeM
Several studies have investigated the interactions between the 
chondroitin sulfate chains of proteoglycans or their degradation 
products and components of the immune system.
It has been reported that CS could stimulate monocytes to 
secrete IL-1β and to induce B cell proliferation in vitro (72). The 
effect of CS on B cell proliferation was corroborated by Aoyama 
et  al., who demonstrated that CS could enhance murine B cell 
proliferation in  vitro through PKC translocation and activa-
tion of protein kinase B (PKB, Akt) kinase (73). A role of CS 
in the maturation of dendritic cells was suggested with human 
monocyte-derived dendritic cells cultured in  vitro in the pres-
ence of CS, hyaluronic acid, components of the ECM and human 
granulocyte-macrophage colony-stimulating factor (GM-CSF). 
CS-stimulated cells could differentiate faster than when cultured 
with GM-CSF and IL-4 (74). Another study utilizing splenocytes 
from ovalbumin (OVA)-immunized mice cultured ex vivo, 
showed that CS addition to culture stimulated secretion of 
Th1-type cytokines including IFN-γ, IL-2, and IL-12 and sup-
pressed the secretion of Th2-type cytokines (IL-5 and IL-10) 
(75). Moreover, injection of BALB/c mice with CS and other 
glycosaminoglycans (GAGs) was shown to induce autoimmune 
conditions like rheumatoid arthritis through recruitment of 
CD4+ T cells (76). In addition, treatment of murine NK cells with 
chondroitinase or a proteoglycan biosynthesis inhibitor resulted 
in substantial decrease in IFN-γ secretion through interaction 
with murine IL-12. On the other hand, CSPG low-molecular 
weight disaccharide fragments could control the inflammatory 
response in a mouse model of autoimmune encephalitis, in a rat 
model of inflammation-mediated neuropathology of the eye, and 
in a delayed-type hypersensitivity model in Balb/c mice through 
reduced migration and activation of inflammatory T cells (77).
With regards to the role of chondroitin sulfate proteoglycans 
(CSPGs), an early study reported these located inside the granules 
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of human NK cells and their exocytosis during NK cell-mediated 
cytotoxicity of tumor cells (78). Furthermore, a study of primary 
cultured human macrophages, showed secreted CSPGs as meta-
bolic products of macrophages and increased secreted CSPG4 
following lipopolysaccharide (79) stimulation (80).
A more recent immune monitoring study identified that both 
healthy individuals and melanoma patients have circulating 
CSPG4-reactive CD4+ T cells. The study did not report a signifi-
cant correlation between the T cell responses against a HLA-DR 
presented CSPG4 peptide, quantified through IFN-γ production, 
and the tumor burden of patients. The authors showed that a 
smaller proportion of the melanoma patients (11 out of 42) 
compared to healthy volunteers (11 out of 13) exhibited T cell 
reactivity to CSPG4 (81). Other in  vivo studies demonstrated 
that LPS induced the expression of the murine CSPG4 ortholog 
by rat microglia cells. Further in  vitro experiments showed 
that NG2 RNA silencing of LPS-treated microglia blocked the 
mRNA expression of nitric oxide synthase (Yajima et al.), and of 
proinflammatory cytokines including IL-1β and tumor necrosis 
factor α (TNF-α), but not of chemokines like monocyte chemoat-
tractant protein 1 and stromal cell-derived factor 1 α (SDF-1α). 
Importantly, this study demonstrated that NG2 is not only 
expressed upon stimulation of the microglia, but it likely has a 
role in regulating expression of pro-inflammatory cytokines (82).
In summary, chondroitin sulfate proteoglycans (CSPGs), 
CS carbohydrate chains, as well as small molecular weight CS 
degradation products and CSPG4, each appear to influence the 
activation, maturation, proliferation and migration of differ-
ent immune cell subsets. The definitive roles for CSPG4 in the 
immunology of cancer are however still widely unexplored. More 
research is required to clarify whether the interactions between 
CSPG4, its amino acid or carbohydrate moieties and different 
components of the immune system could be exploited to enhance 
patient response to CSPG4 targeted immunotherapy or to be 
counteracted to avoid potential negative immunomodulatory 
functions.
CSPG4 AS A TARGeT FOR ANTiBODY 
THeRAPieS iN CANCeR
Since CSPG4 is found to be overexpressed in a number of 
malignancies and based on its low and restricted distribution in 
normal tissues, alongside emerging evidence for crucial roles in 
cancer growth and dissemination, much research has focused on 
the development of different therapeutic approaches, including 
monoclonal antibodies. Some of these antibody-based strategies 
focused on CSPG4 are discussed below.
Classic mAb Approaches
Published studies describe a limited number of mAb clones 
recognizing CSPG4, the most commonly cited of which is 
a murine clone, 225.28. One of the earliest efficacy studies 
reports the antitumor efficacy of the murine 225.28 conjugated 
to methotrexate in nude mice bearing human melanoma xeno-
grafts (83). Even though conjugated mAb had superior efficacy 
to methotrexate alone, the efficacy of the mAb alone was not 
investigated. Melanoma tumor-bearing SCID mice treated with 
the murine mAb 225.28 bore smaller tumors compared with 
controls, and treatments were associated with modulation of 
various tumor suppressor-genes and genes involved in cancer 
metastasis (84). Besides melanoma, this murine mAb was also 
reported to inhibit the proliferation, adhesion and migration 
of TNBC cells, as well as to downregulate tumor-promoting 
signaling pathways in  vitro. Moreover, the murine mAb was 
demonstrated to reduce tumor growth in two human TNBC 
cell line-derived lung metastasis models in SCID mice, and to 
decrease tumor angiogenesis and tumor recurrence after surgi-
cal removal in an orthotopic human TNBC cell line xenograft 
model in SCID mice (61). The murine antibody clone 225.28 
was later also demonstrated to restrict tumor growth synergisti-
cally in combination with BRAF inhibitors in  vitro (51). The 
anticancer potential of mAb 225.28 was tested against 11q23 
ALL cells (71). The mAb on its own showed no direct effects 
on proliferation inhibition in ALL cells in vitro, but it increased 
the efficacy of the chemotherapy agent Cytarabine. The mAb 
225.28 also showed some tumor growth restriction efficacy in a 
subcutaneous ALL model in SCID mice. One of the first stud-
ies reporting an antibody engineered with a human Fc region, 
was of a chimeric version of the mouse mAb 225.28. The study 
showed that this mAb could mediate antibody-dependent cel-
lular phagocytosis (ADCP) by human monocytes in vitro and 
could restrict tumor growth in vivo in a melanoma NOD-SCID-
Gamma (NSG) mouse model engrafted with human immune 
cells (85) Interestingly, anti-CSPG4 IgG4 was demonstrated 
to not only lack tumor inhibition properties in  vivo, but to 
also impair the efficacy of its IgG1 analog when administered 
in combination. This finding highlights the importance of 
choosing appropriate Fc domain and antibody isotype when 
designing therapeutic mAbs. Moreover, the original murine 
anti-CSPG4 clone 225.28 has been reported to exhibit direct 
cancer cell proliferation inhibition properties. In this context, 
the data reported by Karagiannis et al. opens different avenues 
for discussion and future investigation, concerning the effect 
of chimerizing or humanizing mAbs on their direct blockade 
properties, as well as the magnitude of the immunologically 
induced anticancer effects engendered by mAb immunotherapy.
Chondroitin sulfate proteoglycan 4 has also been targeted in 
other malignant indications using different antibody clones. The 
murine mAb clone TP41.2 was used in malignant mesothelioma 
(86). TP41.2 showed in vitro antitumor effects by reducing cancer 
cell proliferation, adhesion, motility, migration and invasion. 
The antibody also reduced tumor growth in vivo and prolonged 
the survival of mesothelioma-bearing SCID mice. In a different 
study by Wang et  al. the authors utilize a single-chain variable 
fragments (scFv) fused to a human IgG1 Fc portion—scFv-FcC21 
and demonstrated growth and migration inhibition of a TNBC 
cell line in vitro, as well as reduction of lung metastasis in a mela-
noma cell line model in SCID mice in vivo (87). The scFc-FcC21 
antibody was shown not to be able to induce antibody-dependent 
cellular cytotoxicity or phagocytosis in  vitro. Furthermore, an 
antimouse CSPG4/NG2 antibody clone 9.2.27 was conjugated to 
polyethylene glycol to increase its affinity for rat FcγRIII on rat 
NK cells, and was used in combination with adoptive NK cells 
in glioblastoma engrafted athymic rats. The combination of 
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adoptive NK  cell transfer and PEGylated mAb 9.2.27 could 
restrict tumor growth in  vivo (88). Curiously, the authors 
accounted the therapeutic efficacy to macrophages recruited to 
the tumor, whose clodronate-mediated depletion abolished the 
antitumor effects of the mAb. The authors suggested that the 
adoptively transferred NK  cell plus mAb treatment might be 
responsible for re-educating tumor-infiltrating macrophages 
to render antitumor functions, however, the exact mechanism 
remains unknown. Interestingly, the antigenic determinants of 
the monoclonal antibodies, described in the above section, have 
been suggested to recognize the CSPG4 core protein indepen-
dently of the presence of chondroitin sulphate (89, 90). It has also 
been proposed that removal of the CS decoration from the core 
CSPG4 protein would not affect the reactivity towards CSPG4 of 
any of the murine clones, mentioned above. Nevertheless, these 
observations require further confirmation (89).
Even though certain anti-CSPG4 antibody clones showed 
promise for therapeutic application in different cancer types and 
in a number of in vitro and in vivo models, most of published 
studies were performed using antibodies with mouse Fc regions. 
With some encouraging findings against CSPG4-expressing 
tumors, the potential of anti-CSPG4 antibodies against cancer 
would benefit from further in-depth research using novel con-
structs including those engineered with human Fc regions.
Anti-idiotypic Antibodies
Early strategies targeting CSPG4 utilized the development of anti-
idiotypic antibodies (anti-id), which target the binding sites of other 
anti-CSPG4 antibodies, essentially mimicking the tumor antigen’s 
binding site on the antibody, and thus aiming to serve as immu-
nogens or vaccines (91, 92). A clinical study reported increased 
survival and metastasis regression in patients with melanoma 
who developed anti-CSPG4 antibodies following administration 
of the anti-idiotypic mAb MK2-23 (93). Despite the promising 
clinical results, MK2-23 never reached clinical application as a 
therapy due to standardization issues and safety concerns linked 
to its administration together with the adjuvant Bacille Calmette-
Guerin (BCG), deemed necessary for triggering effective adaptive 
immune responses (94). Further approaches to overcome those 
issues included fusing MK2-23 to human IL-2 (94) or utilizing 
DNA vaccines encoding MK2-23 scFv (95). In a phase I clinical 
trial, another anti-idiotypic antibody, MF11-30, induced complete 
remission in one advanced melanoma patient as well as conferred 
minor survival benefits in three other patients with advanced 
melanoma whilst no toxicities were reported as a part of Ref. (96).
Another approach concerns vaccine approaches, such as 
mimotope vaccination studies utilizing conformational CSPG4 
epitopes recognized by the 763.74 or the 225.28S anti-CSPG4 
mAb clones. Such strategies have been studied and reported 
induction of CSPG4-specific antibodies in mimotope-vaccinated 
animals, as well as promising antimelanoma activity of these 
antibodies in vitro through direct proliferation inhibition or in 
murine effector cell ADCC assays (97–99).
Even though anti-id antibody strategies or mimotope vaccines 
are currently not in the spotlight, these early studies indicate 
that CSPG4 may be a promising target for vaccine-based cancer 
immunotherapy.
Bispecific T Cell engagers
Bispecific T cell engagers represent a novel therapeutic modality 
based on the fusion of two single-chain variable fragments (scFv), 
one of which binds the target antigen while the other engages with 
T cells via CD3. Unlike classic monoclonal antibodies, BiTEs are 
designed to activate cytotoxic T cells against tumor cells. In 2011, 
a new CSPG4-targeting BiTE antibody was shown to induce 
antitumor effects in  vitro via redirected lysis (100). Following 
incubation with healthy donor PBMCs, all of the 23 melanoma 
cell lines utilized in the study were successfully lysed in a dose- and 
effector:target ratio-dependent manner. Furthermore, the BiTE 
antibody showed promise in a melanoma patient setting in vitro 
by triggering cytotoxicity by melanoma patient-derived T  cells 
against allogeneic or autologous melanoma cells. Another study 
reports important findings about the design of CSPG4-targeting 
BiTE therapeutics linked to the epitope distance to the target cell 
(101). Anti-CSPG4 BiTE antibodies proved much more potent 
when binding epitopes located closer to the cell membrane. This 
was proposed to be linked to the large size of the CSPG4 antigen 
and represents an important factor to consider for the design of 
antibody therapeutic agents with maximal potency.
CAR T Cells
Chimeric Antigen Receptor T  cells represent another promising 
T cell-based therapeutic approach utilizing monoclonal antibodies 
whose efficacy against CSPG4 is being investigated. CAR T cells are 
genetically modified to express a chimeric receptor based on the 
targeting moiety of a mAb (scFv) recognizing the antigen of interest, 
to re-direct cytotoxic T cells toward tumor cells. The robust clinical 
success in the treatment of ALL has attracted a lot of attention on 
CAR T cell approaches, with one anti-CD19 based therapy expected 
to soon be granted FDA approval for the treatment of pediatric 
ALL (102). One of the first studies investigating the potential of 
anti-CSPG4 CAR T cells showed in vitro cytolytic potency against a 
variety of solid tumor cell lines including breast cancer, melanoma, 
mesothelioma, glioblastoma and osteosarcoma (103). Another study 
investigating anti-CSPG4 CAR T cells announced promising effi-
cacy outcomes against melanoma, breast cancer and head and neck 
cancer in vitro and in vivo using cell line xenografts in mice (104).
Even though preclinical data on anti-CSPG4 CAR T  cell 
therapy are encouraging, it remains to be established whether 
the clinical responses observed with CAR T  cell treatments 
against liquid tumors can be reproduced in solid malignancies. 
A prominent limitation of the efficacious re-targeting of T cells 
against solid tumors is the tumor stroma, often inhibiting T cell 
trafficking and potency. Multiple approaches have been designed 
to address this issue, including the expression of chemokine 
receptors by the CAR T cells or in vivo tumor modification to 
encourage the secretion of T cell chemoattractants (105).
Radioimmunotherapy
Monoclonal antibodies recognizing CSPG4 could be conjugated 
to a radioactive isotope for radioimmunotherapy, designed to 
target radiation directly and more specifically to tumor cells, 
with the aim of reducing non-specific exposure of normal cells 
to the radioactive isotope. Targeted radioimmunotherapy may 
TABLe 1 | Antibody-based treatment approaches targeting CSPG4.
Treatment strategy Clone/
construct
Toxin 
conjugate
Treatment 
combination
Antibody species In vitro model 
and indication
In vivo model and 
indication
Proposed mechanism(s) of action Clinical 
trial
Key 
reference
Classic mAb 225.28S MTX N/A Full mouse antibody Melanoma cell 
line
Human melanoma 
cell line xenograft; 
nude mice
Growth inhibition, delivery of cytotoxic 
drugs to the tumor
N/A (83)
Classic mAb 225.28S N/A N/A Full mouse antibody Melanoma, 
TNBC cell line
Human melanoma 
cell line xenograft; 
SCID mice
Disruption of the interaction between 
the cancer cells and the ECM
N/A (84)
Classic mAb 225.28S N/A N/A Full mouse antibody TNBC cell line Human TNBC cell 
line lung metastasis 
model; SCID mice
Direct effects (growth, adhesion, and 
migration inhibition)
N/A (61)
Orthotopic human 
TNBC cell line 
xenograft; SCID mice
Classic mAb 225.28S N/A PLX4032 
(BRAF inhibitor)
Full mouse antibody Human 
BRAFV600E mutant 
melanoma cell 
lines
N/A Synergistic direct effects (growth, 
migration, survival inhibition); delayed 
BRAF inhibitor resistance
N/A (51)
Classic mAb 225.28S N/A Cytarbine 
(chemotherapy)
Full mouse antibody 11q23 AML cell 
line
Human AML cell line 
subcutaneous model; 
SCID mice
No direct effects (mAb alone); 
synergistic antiproliferative effects with 
Cytarbine; no in vivo effects on tumor 
growth/animal survival
N/A (71)
Classic mAb 225.28S N/A N/A Chimeric antibody 
(mouse Fab, human 
Fc)
Melanoma cell 
lines
Human melanoma 
cell line xenograft; 
human immune cell 
engrafted NSG mice
Immune mediated effects (ADCC/
ADCP)
N/A (85)
Classic mAb TP41.2 N/A N/A Full mouse antibody Mesothelioma 
cell line
Human mesothelioma 
cell line xenograft; 
SCID mice
Direct effects (cell growth, adhesion, 
motility, migration, and invasiveness)
N/A (86)
Classic mAb scFv-FcC21 N/A N/A Recombinant scFv 
mAb with a human Fc 
region 
TNBC cell line Human melanoma 
cell line xenograft; 
SCID mice
No immune mediated effects; direct 
effects (cell growth and migration 
inhibition)
N/A (43, 87)
Classic mAb 9.2.27 PEG Adoptive 
NK cell transfer
Full mouse antibody N/A Human GBM cell 
line xenograft, 
patient derived GBM 
xenograft; athymic 
rats 
Immune-mediated effects by 
macrophages
N/A (88)
Classic mAb Polyclonal mAbs N/A Vemurafenib 
(BRAFV600E 
inhibitor)
Full mouse antibody Human 
BRAFV600E mutant 
melanoma cell 
lines
N/A Synergistic direct effects (proliferation 
and migration inhibition)
N/A (117)
Anti-idiotypic mAb MK2-23 N/A BCG Full mouse antibody N/A N/A Induction of adaptive humoral immune 
response
Advanced 
melanoma 
patients; 
Phase I/II
(93)
(Continued)
8
Ilieva et al.
C
S
P
G
4—
A
 C
ancer A
ntibody Im
m
unotherapy Target
Frontiers in Im
m
unology | w
w
w
.frontiersin.org
January 2018 | Volum
e 8 | A
rticle 1911
Treatment strategy Clone/
construct
Toxin 
conjugate
Treatment 
combination
Antibody species In vitro model 
and indication
In vivo model and 
indication
Proposed mechanism(s) of action Clinical 
trial
Key 
reference
Anti-idiotypic mAb MK2-23 IL-2 N/A Full mouse antibody N/A BALB/c mice Induction of adaptive humoral immune 
response
N/A (94)
Anti-idiotypic mAb MF11-30 N/A N/A Full mouse antibody N/A N/A Induction of adaptive humoral immune 
response 
Advanced 
melanoma 
patients; 
2× 
phase I 
(96)
BiTE MCSP-BiTE N/A N/A Recombinant BiTE 
construct 
Human 
melanoma cell 
lines; melanoma 
patient-derived 
samples
N/A Cytotoxic T cell-mediated tumor cell 
killing
N/A (100)
BiTE MCSP120, 
MCSP128, 
MCSP113, 
MCSP70
N/A N/A Recombinant BiTE 
construct based on 
mouse hybridoma-
derived mAbs
CHO cells 
expressing 
CSPG4 domain 
portions
N/A Cytotoxic T cell-mediated tumor cell 
killing
N/A (101)
CAR CAR constructs 
based on mAbs 
225.28; TP41.2; 
149.53
N/A N/A Recombinant CAR 
construct, includes 
mAb scFv region 
based on mouse mAbs
Human 
melanoma, 
breast cancer, 
mesothelioma, 
glioblastoma and 
osteosarcoma 
cell lines
N/A Cytotoxic CAR T cell-mediated tumor 
cell killing
N/A (103)
CAR CAR construct 
based on mAb 
763.74
N/A N/A Recombinant CAR 
construct, includes 
mAb scFv region 
based on mouse mAbs
Human, 
melanoma, 
HNSCC and 
breast cancer 
cell lines
Human, melanoma, 
HNSCC and breast 
cancer cell line 
xenografts; NSG mice
Cytotoxic CAR T cell-mediated tumor 
cell killing
N/A (104)
CAR CAR construct 
based on mAb 
225.28
N/A N/A Recombinant CAR 
construct, includes 
mAb scFv region 
based on mouse mAbs
Human 
melanoma cell 
lines
N/A Cytotoxic CAR T cell-mediated tumor 
cell killing
N/A (119)
Radioimmunotherapy (213)
Bi-cDTPA-9.2.27 
(based on mAb 
9.2.27)
(213)Bi-cDTPA N/A Full mouse antibody N/A N/A Radiotherapy induced targeted 
cytotoxicity 
Advanced 
melanoma 
patients, 
phase I
 (108)
Radioimmunotherapy 225.28S 212Pb N/A Full mouse antibody Human TNBC 
cell line
Human TNBC cell line 
xenograft; nude mice
Radiotherapy induced targeted 
cytotoxicity 
N/A (109)
CFP αCSPG4(scFv)-
MAP
MAP N/A Recombinant 
construct, scFv mAb 
genetically fused to 
MAP
Human TNBC 
cell line
Human TNBC cell line 
xenograft; BALB/c 
mice
MAP induced targeted cytotoxicity N/A (112)
(Continued)
TABLe 1 | Continued
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be promising with regards to CSPG4, based on overexpression 
in advanced tumors, restricted distribution and lower levels of 
expression in normal tissues (106). So far, radioimmunotherapy 
has only been successfully applied for the treatment of patients 
with lymphoma, while most clinical trials in solid tumors have 
rarely reached phase III, often due to cost, or to stringent patient 
inclusion criteria (107). Nevertheless, the outcomes of a phase I 
clinical trial of (213)Bi-cDTPA-9.2.27 (based on the anti-CSPG4 
mAb clone 9.2.27) in advanced melanoma indicated no toxicities, 
a 10% objective partial response rate (108). Furthermore, a more 
recent preclinical study evaluating mAb 225.28 radiolabeled with 
212Pb showed efficacy against triple negative breast cancer cells 
expressing CSPG4, both in vivo and in vitro (109).
Based on these findings, radioactive isotope-conjugated 
anti-CSPG4 antibodies may yet hold promise for patients with 
CSPG4-expressing tumors.
Cytolytic Fusion Proteins (CFPs)
Cytolytic fusion proteins or immunotoxins, are classified as pro-
tein toxins, most commonly of plant or bacterial origin, geneti-
cally fused or conjugated to another protein (often an antibody or 
an antibody fragment), recognizing a cell surface target molecule 
and delivering the payload to the cancer cell (110).
The microtubule-associated protein tau, recently investigated 
as a toxin, primarily functions as a microtubule stabilizer and a 
regulator of cell division (111). Targeting CSPG4 using a scFv 
fused to MAP against TNBC cell lines in vitro and against human 
TNBC cell line xenografts in Balb/c mice showed similar antitu-
mor efficacy to an anti-CSPG4 scFv conjugated to a chemothera-
peutic agent, with no toxic effects in vivo (112).
Another interesting approach involves an anti-CSPG4 scFv 
conjugated to the TNF-related apoptosis-inducing ligand 
(TRAIL), a soluble protein ligand able to induce apoptosis 
through binding the cell surface-anchored TRAIL receptor. In a 
study investigating a TRAIL-fused anti-CSPG4 scFv (based on 
the mAb 9.2.27), the novel therapeutic candidate showed potent 
in  vitro activity against melanoma cell lines, but no off-target 
effects on normal melanocytes (113, 114). Moreover, it restricted 
the growth of a human melanoma xenograft in athymic mice.
Both CFP examples suggest that this may represent a promis-
ing targeted delivery alternative to chemotherapy, especially for 
antigens such as CSPG4 with high expression in tumors and 
restricted expression in normal tissues.
COMBiNATiON THeRAPieS AND OTHeR 
APPLiCATiONS
BRAF inhibitors, now approved for the treatment of patients 
with melanomas bearing mutant forms of BRAF, are often only 
effective for a short time before cancer recurs, due to intrinsic and 
acquired pathway resistance (115). Therefore, alternative treat-
ments and treatment combinations that may overcome resistance 
mechanisms are desirable (116). The anti-CSPG4 mAb 225.28 
combined with a BRAF inhibitor exhibited synergistic antitumor 
effects and enhanced efficacy against BRAFV600E mutant melanoma 
cells in vitro compared to either agent alone (51). Furthermore, 
the mAb was shown to delay the development of resistance by 
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melanoma cells. More recently, Pucciarelli et al. showed that com-
bining polyclonal anti-CSPG4 antibodies, induced by mimotope 
vaccination, with the BRAF inhibitor vemurafenib synergisti-
cally reduced the proliferation and migration of melanoma cells 
in vitro (117). These preliminary findings suggest that combining 
anti-CSPG4 antibodies with pathway inhibitors may enhance the 
restricted success of BRAF inhibitors in melanoma.
Cancer theranostic agents, combining both diagnostic and 
therapeutic treatment in one targeted molecule are an emerging 
modality. As with other antibody therapeutic applications, CSPG4 
has been recognized as a promising candidate for theranostic 
applications, based on high expression by tumor cells and low 
expression by healthy cells. In an in vitro photo-immunotheranostic 
study, single-chain variable fragment (scFv) antibodies recogniz-
ing TNBC targets, including CSPG4, as well as epidermal growth 
factor receptor (EGFR) and epithelial cell adhesion molecule 
(EpCAM), were conjugated to a potent photosensitizing agent and 
were used to target TNBC cell lines and tumor biopsy samples 
(118). The conjugated scFvs demonstrated high quality imaging 
capacity, and triggered apoptosis of cancer cells via induction of 
reactive oxygen species. Moreover, combinatorial administration 
of all three conjugated scFv antibodies together, increased cytotoxic 
activity against breast cancer cells in vitro by up to 40% compared 
with treatment by each individual agent alone. Further findings are 
awaited to confirm and provide further efficacy insights on these 
encouraging outcomes in future in vivo studies.
CONCLUSiON AND FUTURe DiReCTiONS
Despite advances in immunotherapy such as the emergence 
of checkpoint inhibitors for melanoma, mAb, or CAR T  cell 
strategies that specifically target melanoma cells are still lacking. 
Localized overexpression in several aggressive tumor types and in 
tumor vasculature, combined with low and restricted distribution 
in normal tissues, as well as evidence for important functions to 
support cancer growth, angiogenesis and dissemination, repre-
sent important attributes that identify CSPG4 as a promising tar-
get for therapeutic approaches, including monoclonal antibodies 
(Table  1). Importantly, in order to develop more successful 
therapeutics, a better understanding of the functions of CSPG4 
in cancer and its interaction with the immune system and the 
tumor immune stroma are urgently needed.
While many treatment strategies centered on CSPG4 appear 
to have had success both in vitro and in vivo in rodent models, 
the next steps require in-depth studies with humanized or human 
antibodies, in disease-relevant and in clinically congruent models 
of cancer, including animal models engrafted with components 
of human immunity. These will permit mechanistic and efficacy 
evaluations in systems better able to recapitulate the patient setting.
An exciting prospect for targeting CSPG4 is the observed 
synergy between anti-CSPG4 monoclonal antibodies and BRAF 
inhibitors. In melanoma, a proportion of patients’ tumors have 
constitutively activated BRAF. Small molecule inhibitors recog-
nizing mutant forms of BRAF have proved very effective. However, 
clinical responses are often short-lived due to the emergence of 
resistance. Combinatorial studies of monoclonal anti-CSPG4 
antibodies with BRAF inhibitors have demonstrated enhanced 
effects and delayed the occurrence of resistance. Further under-
standing of the mechanisms that underpin the efficacy of these 
and other combinatory strategies may offer important clues that 
stand to improve current treatments.
Additionally, targeting CSPG4 may lead to targeted therapy 
for triple-negative breast cancer patients who do not benefit from 
therapies apart from standard chemotherapy. Therefore, further 
research and translation into clinical trials could be especially 
beneficial for the TNBC patient group.
As with all therapeutic approaches, the benefits of treatment 
must be balanced with the likelihood and severity of adverse 
effects. CSPG4 is expressed at low levels in some normal tis-
sues; therefore, it is important to evaluate and mitigate any on-
target, off-tumor toxic effects of CSPG4-specific targeted therapy. 
Encouragingly, a phase I clinical trial investigating anti-CSPG4 
radioimmunotherapy with a mAb (9.2.27) conjugated to an 
α-particle-emitting radioisotope which was administered sys-
temically in patients with melanoma reported no adverse events 
while some clinical benefits were observed (108). Furthermore, 
CSPG4-based immunotherapy strategies would benefit from the 
development of more effective methods of treatment delivery, such 
as hypobaric pressure skin delivery, which would limit potential 
off-target effects and reduce the cost of the therapy (120).
The emergence of novel antibody-based approaches offers fresh 
optimism that aggressive cancers, such as TNBC, glioma and head 
and neck carcinomas, which do not benefit from currently available 
therapies, but for which CSPG4 expression and its tumor-promoting 
functions have been reported, may become responsive to treatments 
based on this target. Therefore, renewed focus on CSPG4 may in 
future translate into significant benefits for patients with cancer.
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